Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
59 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Ocular Pain - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Ocular Pain - Pipeline Review, H2 2014', provides an overview of the Ocular Pain's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Ocular Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Pain and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Ocular Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ocular Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ocular Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Ocular Pain pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ocular Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ocular Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Ocular Pain Overview 7 Therapeutics Development 8 Pipeline Products for Ocular Pain - Overview 8 Pipeline Products for Ocular Pain - Comparative Analysis 9 Ocular Pain - Therapeutics under Development by Companies 10 Ocular Pain - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Ocular Pain - Products under Development by Companies 14 Ocular Pain - Companies Involved in Therapeutics Development 15 Bayer AG 15 InSite Vision Incorporated 16 Kala Pharmaceuticals, Inc. 17 Reata Pharmaceuticals, Inc. 18 Sylentis S.A. 19 Ocular Pain - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 dexamethasone - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 fluticasone propionate - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 ISV-303 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 ketorolac tromethamine - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 loteprednol etabonate - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 mapracorat - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 NT-71 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 NT-72 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 RTA-408 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 SYL-1001 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Ocular Pain - Recent Pipeline Updates 41 Ocular Pain - Dormant Projects 49 Ocular Pain - Product Development Milestones 50 Featured News & Press Releases 50 Oct 01, 2013: InSite Vision Completes Enrollment of Confirmatory Phase 3 Clinical Study of BromSite for the Reduction of Inflammation and Pain after Cataract Surgery 50 May 09, 2013: InSite Vision Initiates Confirmatory Phase III Clinical Study Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery 50 Apr 25, 2013: Pharm-Olam Completes Phase III Ophthalmology Study Of InSite Vision's Bromsite 51 Mar 18, 2013: InSite Vision Reports Positive Phase III Results Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery 51 Jan 10, 2013: InSite Vision Completes Phase III Clinical Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery 52 Nov 29, 2012: InSite Vision Completes Patient Enrollment In Phase III Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery 53 Jul 31, 2012: InSite Vision Initiates First Phase III Clinical Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery 53 Mar 22, 2011: InSite Vision Announces Positive Phase I/II Results For ISV-303 For Reduction Of Pain And Inflammation After Cataract Surgery 54 Jan 05, 2011: InSite Vision Completes Patient Enrollment In ISV-303 Phase I/II Clinical Study For Post-Surgical Ocular Pain And Swelling 55 Dec 15, 2009: InSite Vision To Advance New Ocular Anti-Inflammatory Candidate 56 Appendix 58 Methodology 58 Coverage 58 Secondary Research 58 Primary Research 58 Expert Panel Validation 58 Contact Us 59 Disclaimer 59
List of Tables Number of Products under Development for Ocular Pain, H2 2014 8 Number of Products under Development for Ocular Pain - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 10 Comparative Analysis by Late Stage Development, H2 2014 11 Comparative Analysis by Clinical Stage Development, H2 2014 12 Comparative Analysis by Early Stage Development, H2 2014 13 Products under Development by Companies, H2 2014 14 Ocular Pain - Pipeline by Bayer AG, H2 2014 15 Ocular Pain - Pipeline by InSite Vision Incorporated, H2 2014 16 Ocular Pain - Pipeline by Kala Pharmaceuticals, Inc., H2 2014 17 Ocular Pain - Pipeline by Reata Pharmaceuticals, Inc., H2 2014 18 Ocular Pain - Pipeline by Sylentis S.A., H2 2014 19 Assessment by Monotherapy Products, H2 2014 20 Number of Products by Stage and Target, H2 2014 22 Number of Products by Stage and Mechanism of Action, H2 2014 24 Number of Products by Stage and Route of Administration, H2 2014 26 Number of Products by Stage and Molecule Type, H2 2014 28 Ocular Pain Therapeutics - Recent Pipeline Updates, H2 2014 41 Ocular Pain - Dormant Projects, H2 2014 49
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.